SiBone (NASDAQ:SIBN) CEO Laura Francis Sells 3,923 Shares

SiBone (NASDAQ:SIBN) CEO Laura Francis sold 3,923 shares of the business’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $20.02, for a total value of $78,538.46. Following the transaction, the chief executive officer directly owned 317,463 shares of the company’s stock, valued at $6,355,609.26. The trade was a 1.22% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Laura Francis also recently made the following trade(s):

• On Thursday, August 20th, Laura Francis sold 51,884 shares of SiBone stock. The shares were sold at an average price of $19.46, for a total transaction of $1,009,662.64.

SiBone Price Performance

SiBone stock traded up $0.48 during mid-day trading on Friday, hitting $19.96. 1,290,316 shares of the company traded hands, compared to its average volume of 620,561. The company has a debt-to-equity ratio of 0.20, a quick ratio of 7.55 and a current ratio of 9.15. SiBone has a one year low of $11.48 and a one year high of $21.89. The stock has a market cap of $885.21 million, a price-to-earnings ratio of -58.71 and a beta of 0.66. The stock has a fifty day moving average price of $17.40 and a 200-day moving average price of $15.30.

SiBone (NASDAQ:SIBN) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.06. The firm had revenue of $56.01 million for the quarter, compared to analyst estimates of $55.34 million. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.23%. On average, equities analysts predict that SiBone will post -0.4 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. UBS Group lifted their price target on SiBone from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Weiss Ratings raised SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. TD Cowen boosted their target price on SiBone from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Finally, Truist Financial reiterated a “buy” rating and set a $23.00 price target (up from $21.00) on shares of SiBone in a research report on Tuesday, August 4th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, SiBone has an average rating of “Moderate Buy” and an average price target of $24.17.

Institutional Investors Weigh In On SiBone

Hedge funds and other institutional investors have recently modified their holdings of the stock. Versant Capital Management Inc boosted its holdings in SiBone by 102.9% during the 2nd quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock valued at $29,000 after acquiring an additional 887 shares during the period. Bank of America Corp DE increased its stake in SiBone by 8.7% in the 1st quarter. Bank of America Corp DE now owns 419,473 shares of the company’s stock worth $5,298,000 after purchasing an additional 33,688 shares during the period. ADAR1 Capital Management LLC purchased a new position in SiBone in the 1st quarter worth approximately $159,000. Quantinno Capital Management LP lifted its position in SiBone by 58.2% in the first quarter. Quantinno Capital Management LP now owns 29,475 shares of the company’s stock valued at $372,000 after purchasing an additional 10,848 shares during the last quarter. Finally, First Light Asset Management LLC lifted its position in SiBone by 6.4% in the first quarter. First Light Asset Management LLC now owns 5,353,190 shares of the company’s stock valued at $67,611,000 after purchasing an additional 320,286 shares during the last quarter. Institutional investors own 98.11% of the company’s stock.

About SiBone

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.